With an FDA decision looming, Flexion touts new data spotlighting a safety edge for osteoarthritis drug
Now that Flexion $FLXN is less than four months away from an FDA decision on its new osteoarthritis drug Zilretta (FX006), the biotech has floated some new data from a tiny mid-stage study that it’s hoping will find its way into the label.
The Burlington, MA-based group turned up at the ADA meeting in San Diego over the weekend to say that it now has data to prove that its drug is not associated with the same spikes in blood glucose that diabetics commonly experience when they get a steroid shot in an aching joint. And they’re looking to use it to gain a leg up in a sizable market.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.